RNA Targeting in Alpha-Synucleinopathies

ABSTRACT

Therapies and assays to screen for small molecules that can have therapeutic use in the control of neurodegenerative diseases such as Parkinson&#39;s and other alpha-synucleinopathies.

This application claims priority to U.S. Provisional Application No.61/215,556, filed May 6, 2009, the contents of which are herebyincorporated by reference in its entirety.

FIELD OF USE

This invention relates to therapies and assays to screen for smallmolecules that can have therapeutic use in the control ofneurodegenerative diseases such as Parkinson's and otheralpha-synucleinopathies.

BACKGROUND

Neurodegenerative diseases such as Parkinson's disease and otheralpha-synucleinopathies are chronic debilitating disorders for which nocure is known.

Parkinson's disease (PD) is a common neurodegenerative disorder thataffects 1% of the population over 65. It is characterized by disablingmotor abnormalities including tremor, slow movements, rigidity and poorbalance. These impairments stem from the progressive loss ofdopaminergic neurons in the substantia nigra pars compacta. Eventually,large percentages of patients develop dementia and hallucinations whenthe pathology involves other brain regions as well. Although themajority of Parkinson cases appear to be sporadic, the disorder runs infamilies in about 15-20% of the cases. To date, five distinct genes havebeen identified to cause PD including α-synuclein, parkin, dj-1, pink1and lrrk2 1. Understanding how mutations in these genes causeneurodegeneration is crucial in the development of new treatments thatmight slow or stop the disease progression. Thus there remains a needfor new treatments for the disease progression and for assays to helpidentify agents for such treatment.

Accumulating evidence indicates that increased levels of the proteinα-synuclein is deleterious to neurons and can lead to such disordersincluding Parkinson's disease. This invention relates to theidentification of a new mechanism by which the expression of thisprotein can be down-regulated by targeting its RNA. The study of andcontrol of this heretofore unrecognized mechanism can be used as atherapeutic target and to screen small molecules that can mimic theeffect for therapeutic intent in these diseases.

SUMMARY OF THE INVENTION

The present invention is related to treatments of neurodegenerativediseases associated with excess α-synuclein (α-Syn) expression viamiRNAs, and mimics thereof, which suppress α-synuclein expression and/orinhibit α-synuclein-mediated cell death.

Therefore, in certain embodiments, the present invention is directed toa method for the treatment of a neurodegenerative disease associatedwith increased levels of α-synuclein comprising administering aneffective amount of a substance that suppresses α-synuclein expressionto a patient in need thereof.

In other embodiments, the present invention is directed to a method fortreating a neurodegenerative disease comprising administering aneffective amount of a miRNA or a mimic thereof to a patient in needthereof, wherein the miRNA is selected from the group consisting ofmiRNA-7, miRNA-153, miRNA-223, miRNA-504, miRNA-920, miRNA-34b,miRNA-374, miRNA-129, miRNA-144, miRNA-143, miRNA-148, and miRNA-433.

In preferred embodiments, the neurodegenerative diseases includeParkinson's disease, dementia with Lewy bodies, multiple system atrophy,and other α-synucleinopathies.

In certain embodiments, the present invention is directed to a methodfor suppressing α-synuclein expression in a subject comprisingadministering an effective amount of miRNA or a mimic thereof to asubject.

In yet other embodiments, the present invention is directed to a methodfor inhibiting α-synuclein-mediated cell death in a subject comprisingadministering an effective amount of a miRNA or a mimic thereof to asubject.

In certain embodiments, the present invention is directed to acomposition comprising a miRNA or mimic thereof which suppressesα-synuclein expression in a subject or inhibits α-synuclein-mediatedcell death in a subject.

As used herein, the phrase “effective amount” means an amount forproviding the therapeutic effect of the composition or substance beingadministered.

As used herein, the term “mimic” refers to a composition which, althoughstructurally different, exhibits the same mechanism of action or effectof another composition or substance, thereby producing the same oressentially the same end result.

As used herein, the term “patient” refers to a mammal, human orotherwise, suffering from a disease or condition.

As used herein, the term “subject” refers to organisms to be treated bythe methods of the present invention. Such organisms can be any type oforganism, e.g., single-cell organisms to more complex organisms such aseukaryotes (e.g., rodents, bovines, porcines, canines, felines, and thelike). For the purposes of this application, the term “subject” alsoincludes any substance derived from an organism, for example, a subjectmay be cellular tissue derived from a mammal used in in-vitro testing.

As used herein the term “treating” includes abrogating, substantiallyinhibiting, slowing or reversing the progression of a condition,substantially ameliorating clinical or aesthetical symptoms of acondition, substantially preventing the appearance of clinical oraesthetical symptoms of a condition, and protecting from harmful orannoying stimuli.

It must be noted that as used herein and in the appended claims, thesingular forms “a”, “and”, and “the” include plural references unlessthe context clearly dictates otherwise.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Although any methods andmaterials similar or equivalent to those described herein can also beused in the practice or testing of the present invention, the preferredmethods and materials are now described.

BRIEF DESCRIPTION OF THE FIGURES

The invention is more fully disclosed below in conjunction with theattached Figures wherein:

FIGS. 1A, 1B, 1C and 1D show miR-7 regulates endogenous α-Syn levels.

FIG. 1A depicts a schematic diagram of human α-Syn mRNA containing thepredicted conserved target site of miR-7.

FIG. 1B depicts a Western blot using SYN-1 antibody to show miR-7reduces the level of endogenous α-Syn in HEK293T cells.

FIG. 1C depicts mean levels of α-Syn protein in FIG. 1B calculated fromthree independent experiments.

FIG. 1D depicts quantitative RT-PCR analysis of α-Syn and EGFR mRNAexpression in HEK293T cells.

FIGS. 2A, 2B and 2C show miR-7 acts on the 3′-UTR of α-Syn mRNA.

FIG. 2A depicts schematic diagrams of human α-Syn 3′-UTR luciferaseconstructs showing wild-type and mutant (α-Syn-3′-mUTR) miR-7 targetsequences.

FIG. 2B depicts the level of luciferase activities of HEK293T cellstransfected with luciferase constructs shown in FIG. 2A and 40 nM miR-7and harvested 24 h later.

FIG. 2C depicts the level of luciferase activities of HEK293T cellstransfected with pri-miR-7-2.

FIGS. 3A, 3B and 3C show miR-7 inhibitor increases α-Syn protein level.

FIG. 3A shows a representative Western blot using SYN-1 antibody ofSH-SY5Y cells transfected with the indicated concentrations ofanti-miR-7 inhibitor (2′-O-methyl) and harvested 48 h later.

FIG. 3B depicts the mean amount of α-Syn measured from three independentexperiments normalized to β-actin.

FIG. 3C depicts the levels of luciferase activity of SH-SY5Y cellstransfected with luciferase constructs and 50 nM 2′-Omethyl inhibitor ofmiR-7 and harvested 24 h later.

FIGS. 4A, 4B, 4C, 4D and 4E show miR-7-mediated reduction of α-Syn levelprotects against proteasome impairment and cell death.

FIG. 4A depicts a schematic diagram of A53T mutant α-Syn construct withor without its 3′-UTR.

FIG. 4B depicts a representative Western blot using LB509 antibody ofmouse neuroblastoma NS20Y cells transfected with constructs shown inFIG. 4A along with 50 nM miR-7 or control (scrambled miR sequence).

FIG. 4C depicts the average relative level of α-Syn (A53T) measured fromthree independent experiments normalized to EGFP expression.

FIG. 4D depicts chymotryptic proteasome activity measured in NS20Y cellstransfected and harvested 24 h later.

FIG. 4E depicts the % of cell death from NS20Y cells transfected withα-Syn (A53T) constructs in the absence or presence of miR-7.

FIG. 5 depicts the relative miR-7 expression in the mouse brain.

DETAILED DESCRIPTION

α-Synuclein (α-Syn) is a key player in the pathogenesis of PD based ongenetic, neuropathologic and cellular/molecular lines of evidence. Inaddition to point mutations linked to dominantly inherited PD, mountingevidence suggests that elevated levels of α-Syn are deleterious todopaminergic neurons. Individuals with multiplication of this gene locusdevelop PD with an earlier onset age and increasing severity associatedwith dementia in a gene dosage dependent manner, transgenic mice,drosophila and C. elegans over-expressing α-Syn manifest phenotypicchanges reminiscent of the disease, and engineered cultured cells aremade vulnerable by this protein. In addition, a large-scale analysis inpatients with PD and controls showed that variability in the α-Synpromoter region, which results in its up-regulation, is associated withan increased risk of PD. Besides these compelling data, postmorteminvestigations of PD and other α-synucleinopathies have demonstratedfibrillar α-Syn aggregates in Lewy bodies and Lewy neurites. Animmunization approach to clear the brain of the α-Syn burden has beenshown to reduce the neurodegeneration in transgenic mice. Based on theaforementioned evidence, α-Syn over-expression appears to be a commonmechanism for the pathogenesis of PD and other α-synucleinopathies.

MicroRNAs (miRNAs) are a class of endogenous 17-24 base-longsingle-stranded, non-coding RNAs that regulate gene expression in asequence-specific manner in plants and animals. miRNAs are derived fromlong precursor transcripts by the action of nucleases Drosha and Dicer,and the resulting mature functional miRNAs bind to their target sequencein the 3′ untranslated region (UTR) of mRNA with imperfectcomplementarity and lead to repression of translation. Recently, miRNAshave been suggested to play important roles in diverse biologicalphenomena including development, oncogenesis and brain functions. SomemiRNAs are specifically expressed and enriched in the brain, and havebeen associated with memory, neuronal differentiation and synapticplasticity. The role of miRNAs in neurodegeneration has been suggestedin several reports. Interestingly, miR-133b, which is specificallyexpressed in midbrain dopaminergic neurons and controls their maturationand function through its effect on the homeodomain transcription factorPitx3, is deficient in PD brains, suggesting that miR-133b is essentialfor the maintenance of these neurons and could therefore play a role inPD pathogenesis.

It has now been found that miR-7 represses α-Syn expression and inhibitsα-Syn-mediated cell death.

Increased α-Syn gene (SNCA) dosage due to locus multiplication leads toautosomal dominantly inherited PD, suggesting that higher concentrationof α-Syn protein in neurons is involved in the pathogenesis of PD. Insporadic PD, it is conceivable that various genetic or environmentalfactors that up-regulate α-Syn expression can be potential culprits aswell. Recent evidence suggests that miRNAs regulate a plethora of genesand are involved in many disease states ranging from cancer toneurodegeneration. In the examples which follow, the first experimentalevidence for a specific miRNA species that directly represses α-Synprotein levels and protects against α-Syn-mediated cytotoxicity isdescribed.

miR-7, which is a brain-enriched miRNA, binds to the 3′UTR of α-Syn mRNAin a sequence dependent manner and significantly inhibits itstranslation. GenBank BLAST search revealed that miR-7 is found in human,mouse, rat, zebra fish and fly, suggesting that it regulates biologicalfunctions conserved between vertebrates and invertebrate. Antisenseinhibition of miR-7 has been found to down-regulate cell growth andincrease apoptosis, suggesting that miR-7 has a protective role. Thelatter finding is consistent with observation that miR-7 suppressesα-Syn mediated cell death. In contrast, miR-7 can also have tumorsuppressor-like characteristics in glioblastomas. It potentlydown-regulates the EGF receptor (EGFR) as well as upstream players ofthe Akt pathway. Additionally, miR-7 is down-regulated in humanglioblastoma tissue relative to surrounding normal brain. The apparentdiscrepancy between the anti- and pro-cell death activity of miR-7 mightreflect the complex regulatory role of this microRNA, requiringadditional investigations into its biology in different cellularcontexts.

miR-7 is transcribed from three loci in the human genome and one locusof the mouse genome. miR-7-1 is located within an intron of the HNRNPKgene on chromosome 9, which encodes a ribonucleoprotein. ProfilingmicroRNA expression in various tissues has found miR-7 highly expressedin the pituitary gland, presumably because miR-7-3 is transcribed froman intron of pituitary gland-specific factor 1a (PGSF1) gene.

Based on the prediction algorithm of Target Scan v5.1, miRNA-153,miRNA-223, miRNA-504, miRNA-920, miRNA-34b, miRNA-374, miRNA-129,miRNA-144, miRNA-143, miRNA-148, and miRNA-433, based on their similarcharacteristics to miR-7, will also repress α-Syn expression and inhibitα-Syn-mediated cell death. Some of these target sequences in the 3′-UTRof α-Syn are highly conserved.

The present finding pointing to the importance of the 3′-UTR and miRNAtarget sites in controlling α-Syn expression also raises the possibilityof polymorphisms at these sites contributing to PD susceptibility.Several polymorphisms in the 3′-UTR of the human α-Syn gene are reportedin GeneBank but not in the target sites of miR-7 or miR-153. Instead, apolymorphic variation (rs10024743) lies in the potential target site ofmiR-34b. A polymorphic variation in the miR-433 binding site of thefibroblast growth factor 20 (FGF20) gene was recently reported to conferrisk of PD which was attributed to increasing FGF20 levels andindirectly α-Syn expression.

Several studies have implicated miRNAs in brain diseases. For example, amutation in the target site of miR-189 in the human SLITRK1 gene hasbeen shown to be associated with Tourette's syndrome. In addition,conditional deletion of Dicer in murine post-mitotic Purkinje cellsresulted in progressive loss of miRNAs, cerebellar degeneration andataxia. miRNAs regulate the expression of ataxin1, amyloid precursorprotein (APP) and BACE1, and have been suggested to contribute toneurodegenerative disorders. These observations and our present findingsraise the possibility that mutations in miR-binding sites or in miRgenes themselves can trigger neurodegenerative disease.

Inhibitors of α-Syn expression are attractive therapeutic targets for PDand other αsynucleinopathies. The results shown here provide a newtarget that can accomplish this objective and potentially slow or haltPD progression.

To that end, the miRNAs described herein, and small molecules whichmimic the effects of such miRNAs, may be administered to a subject orpatient to treat neurodegenerative diseases associated with excess α-Synexpression. When administered to a subject or patient, the miRNA can beadministered as a component of a composition that comprises apharmaceutically acceptable carrier or excipient. In certainembodiments, the compositions of the invention can be administered byinfusion or bolus injection, by absorption through epithelial ormucocutaneous linings (e.g., oral mucosa, rectal, and intestinal mucosa,etc.), by oral administration, and can be administered together withanother therapeutic agent. Administration can be systemic or local.Various delivery systems are known, e.g., viral vectors, encapsulationin liposomes, microparticles, microcapsules, capsules, etc., and can beused to administer the composition comprising miRNA described herein ormimic thereof.

Methods of administration include but are not limited to intradermal,intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal,epidural, oral, sublingual, intracerebral, intravaginal, transdermal,rectal, by inhalation, or topical, particularly to the ears, nose, eyes,or skin.

The compositions can optionally comprise a suitable amount of apharmaceutically acceptable excipient so as to provide the form forproper administration to the subject or patient. Such pharmaceuticalexcipients can be liquids, such as water and oils, including those ofpetroleum, animal, vegetable, or synthetic origin, such as peanut oil,soybean oil, mineral oil, sesame oil and the like. The pharmaceuticalexcipients can be saline, gum acacia, gelatin, starch paste, talc,keratin, colloidal silica, urea, and the like. In addition, auxiliary,stabilizing, thickening, lubricating, and coloring agents may be used.When administered to a patient, the pharmaceutically acceptableexcipients are, in certain embodiments, sterile. Suitable pharmaceuticalexcipients also include starch, glucose, lactose, sucrose, gelatin,malt, rice, flour, chalk, silica gel, sodium stearate, glycerolmonostearate, talc, sodium chloride, dried skim milk, glycerol,propylene, glycol, water, ethanol, and the like.

The following examples are set forth to assist in understanding theinvention and should not, of course, be construed as specificallylimiting the invention described and claimed herein. Such variations ofthe invention, including the substitution of all equivalents now knownor later developed, which would be within the purview of those skilledin the art, and changes in formulation or minor changes in experimentaldesign, are to be considered to fall within the scope of the inventionincorporated herein.

EXAMPLES Example 1 Identification of miR-7 as a Regulator of α-SynExpression

The human α-Syn gene has a 3′ UTR that is more than twice as long as itsopen reading frame (ORF), raising the possibility that it might containpost-transcriptional regulatory elements that would control its proteinlevel. To search for miRNA(s) that might regulate human α-Synexpression, we utilized public prediction algorithms found in severalweb sites, such as miRbase (http://microrna.sanger.ac.uk/sequences/),Targetscan (http://www.targetscan.org/), Pictar(http://pictar.mdc-berlin.de/), and miRanda(http://www.microrna.org/microrna/home.do). A number of miRNA targetsequences were predicted and described above. miRNA-7 (miR-7) was commonto all predictions. Expression of miR-7 was previously verified inhuman, mouse and zebra fish and found to be especially enriched in thebrain. FIGS. 1A-D show miRNA-7 regulates endogenous α-Syn levels. Theseed match between miR-7 and α-Syn 3′-UTR is between bases 119 and 127,and this target region is conserved in human, mouse, rat, dog andchicken (FIG. 1A). The free energy required for the interaction betweenmiR-7 and its cognate α-Syn 3′-UTR binding site is −22.7 kcal/mol basedon the Pictar prediction.

To test the role of miR-7 in regulating α-Syn protein expression,HEK293T cells, which express significant amounts of endogenous α-Syn,were transfected with pre-miR-7 duplex at two concentrations andharvested 48 h later. miR-7 reduced α-Syn expression dose-dependently:40 nM miR-7 resulted in 40% reduction of α-Syn expression, and 80 nMmiR-7 reduced it by 50% (FIG. 1B,C). Endogenous levels of α-Syn in humandopaminergic neuroblastoma. SH-SY5Y and mouse neuroblastoma NS20Y cellsare too low to detect the effect of miR7 (Data not shown).

Next, we investigated the effect of miR-7 on α-Syn mRNA levels byquantitative RTPCR. Transfection of HEK293T cells with 40 nM miR-7significantly reduced α-Syn mRNA expression by 34% (FIG. 1D), indicatingthat miR-7 promotes the degradation of this target mRNA. Both mRNAexpressions are normalized to GAPDH mRNA, and are shown as a ratio tocontrol (scrambled miR-7 sequence)-transfected cells. Experiments weredone in triplicates. Data are shown as means±S.D. *P<0.01 for differencebetween control and miR-7 treated samples. As positive control in thisexperiment, miR-7 also reduced Epidermal Growth Factor Receptor (EGFR)mRNA expression by 57%, as reported previously.

Repression of α-Syn Expression by miR-7 Requires α-Syn 3′-UTR.

To test if miR-7 directly targets the 3′-UTR of α-Syn, this full-length3′-UTR was inserted downstream of the firefly luciferase reporter gene(FIG. 2A) and co-transfected with duplex miR-7 into HEK293T cells. miR-7significantly decreased luciferase activity from α-Syn-3′-UTR constructin a dose-dependent manner, but had no effect on pGL3-pro construct,which lacks α-Syn 3′-UTR (FIG. 2B). As positive control, miR-7significantly inhibited luciferase activity from EGFR-3′-UTR-containingconstruct by 50% (FIG. 2B), consistent with previous reports. The effectof miR-7 on the α-Syn 3′-UTR in a luciferase construct was alsoreplicated in SH-SY5Y cells. To confirm that the predicted targetsequence of miR-7 in the α-Syn 3′-UTR is functional, this site wasmutagenized as shown in FIG. 2A. Notably, miR-7 could not inhibitluciferase activity from the mutagenized α-Syn-3′-UTR construct (FIG.2B) indicating that the predicted sequence is indeed a genuine bindingsite for miR-7. Further, we confirmed the effect of miR-7 on α-Synexpression using a pri-miR-7-2 vector expressing miR-7. Transfection ofHEK293T cells with pri-miR-7-2 consistently inhibited luciferaseactivity from constructs having α-Syn-3′-UTR as well as EGFR-3′-UTR butnot from α-Syn-3′-UTR mutated at the miR-7 seed sequence (FIG. 2C). Thisexperiment also shows that HEK293T cells can efficiently processpri-miR-7 to mature functional miR-7. *P<0.05, **P<0.01 for differencebetween control and miR-7-treated samples.

miR-7 Inhibitor Up-Regulates α-Syn Expression.

Anti-miR™ miRNA Inhibitors are chemically modified (2′-O-methyl),single-stranded nucleic acids designed to specifically bind to andinhibit endogenous miRNAs. By using this specific inhibitor againstmiR-7, we found that endogenous level of α-Syn protein was significantlyincreased in SHSY5Y cells (FIG. 3A,B). In addition, luciferase activityfrom the plasmid containing α-Syn-3′-UTR also increased significantly inthe presence of miR-7 inhibitor, whereas those from constructs havingα-Syn mutant 3′UTR (α-Syn-3′-mUTR) or no 3′-UTR (pGL3-pro) were notaffected (FIG. 3C). Once again, as positive control, EGFR-3′-UTRresponded by increased expression in the presence of miR-7 inhibitor.These results confirm that miR-7 inhibits α-Syn expression through the3′-UTR, and further suggest that endogenous miR-7 actively suppressesα-Syn expression in SH-SY5Y cells, which could be blocked by miR-7inhibitor. *P<0.05, **P<0.01 for difference between control and miR7inhibitor treated samples.

MirR-7 Protects Against α-Syn-Induced Proteasome Inhibition andCytotoxicity.

α-Syn over-expression and particularly its PD causing A53T mutantincreases the susceptibility of cells to oxidative stress, which is aconsistent abnormality in the PD brain. Further, the A53T mutant form ofα-Syn reportedly impairs proteasome activity. To investigate if miR-7regulates α-Syn-mediated proteasome inhibition and cytotoxicity, wegenerated constructs expressing the α-Syn open reading frame harboringthe A53T mutation with or without its full length 3′-UTR (FIG. 4A).Cotransfecting miR-7 along with these constructs significantly reducedα-Syn (A53T) expression from the 3′-UTR containing plasmid but not fromthe construct lacking the 3′UTR (FIG. 4B,C). pEGFP-C1 was used asinternal control for normalization of transfection efficiency.Interestingly, even in the absence of exogenous miR-7 transfection, theamount of human α-Syn protein expressed from the construct without3′-UTR was 2-fold higher than that from the construct with 3′-UTR,suggesting that endogenous mouse miRNA(s) act on the 3′-UTR of thisconstruct. As shown in FIG. 4D, A53T mutant α-Syn expression resulted ininhibition of chymotryptic proteasome activity regardless of thepresence of the 3′-UTR, while co-expression of miR-7 significantlyrecovered this proteasome activity only in the presence of α-Syn 3′-UTR.Cells were also transfected with pSV-β-Gal plasmid as an internalcontrol for transfection efficiency, and proteasome activity values werenormalized with β-galactosidase activity. Experiments were done intriplicates. Additionally, miR-7 recovered tryptic and post-acidicproteasome activities inhibited by A53T α-Syn.

Next, the cytotoxicity of mutant α-Syn was tested. Since NS20Y cells donot manifest toxicity to the mere expression of α-Syn (A53T), they werealso challenged with hydrogen peroxide. As expected, A53T α-Syntransfected cells demonstrated increased sensitivity to H2O2 compared toempty vector transfected cells (FIG. 4E). pSV-β-Gal plasmid was used asinternal control for normalization of transfection efficiency. Aftertransfection, cells were treated with 200 μM H2O2 for 16 h. Experimentswere performed in triplicates and repeated independently three times.*P<0.05, **P<0.005 for difference between control and miR-7-treatedsamples. Notably, in the presence of miR-7 and α-Syn (A53T)-3′-UTR,H2O2-induced cell death was significantly reduced down to the toxicityseen with empty vector transfected cells (FIG. 4E). However, miR-7 didnot suppress H2O2-induced cell death in α-Syn (A53T) expressing cellslacking the 3′-UTR or in empty vector transfected cells. Thus, miR-7completely protects against A53T mutant α-Syn mediated susceptibility toH2O2 in an α-Syn 3′-UTR dependent manner. Taken together, these resultsindicate that miR-7 inhibits α-Syn expression and thereby protectsagainst α-Syn-mediated proteasome impairment and susceptibility tooxidative stress.

miR-7 Expression in the Mouse Brain.

Nigral dopaminergic neurons are vulnerable in PD where accumulated α-Synmight cause toxicity. To study the possibility that α-Syn expression inthe substantia nigra could be regulated by miR-7, we investigated thelevel of miR-7 in this and several other regions of the mouse brain byqRT-PCR analysis (FIG. 5). Total RNA samples isolated from brain regionswere used for qRT-PCR analysis of miR-7. Amounts are calculated relativeto the level in substantia nigra.

As reported, miR-7 expression is highest in the pituitary gland,validating the quality and specificity of this experiment.Interestingly, the substantia nigra, striatum (where nigral dopaminergicnerve terminals project) and olfactory bulb, which are neural systemsaffected in PD, have relatively higher miR-7 levels compared to thecerebral cortex and cerebellum, raising the possibility thatdysregulation of miR-7 in these regions might relate to PD pathogenesis.

Materials and Methods Cell Culture, Transfection and Luciferase Assay.

Human embryonic kidney cell line HEK293T and human neuroblastoma cellline SH-SY5Y were obtained from American Type Culture Collection (ATCC),and mouse neuroblastoma cell line NS20Y was a kind gift from Dr.Marshall Nirenberg (NHLBI, NIH, Bethesda, Md.). All cells weremaintained in Dulbecco's modified Eagle's medium (DMEM) containing 10%fetal bovine serum. Pre-miRNA-7 and miRNA-7 inhibitor were purchasedfrom Ambion. Transfections were performed using Lipofectamine 2000reagent (Invitrogen) according to the supplier's instructions. Forluciferase assay, cells were co-transfected with luciferase reporterconstructs and internal control construct pSV-β-galactosidase in theabsence or presence of miR-7 or pre-miR-7 at the indicatedconcentrations. After cell lysis, luciferase activity was measured withSteady-Glo Luciferase Assay System (Promega) using Luminometer (Victor2,Perkin Elmer). β-Galactosidase activity was measured with theβ-Galactosidase Enzyme Assay System (Promega) and used to normalizeluciferase activity. Experiments were performed in triplicates.

Plasmids.

3′-UTR containing reporter plasmids were constructed by inserting thehuman α-Syn 3′-UTR into the XbaI site located downstream of theluciferase gene in the pGL3 promoter plasmid (Promega), and namedα-Syn-3′-UTR. In addition, this 3′-UTR was inserted downstream of humanwild-type or A53T mutant α-Syn coding sequence. α-Syn 3′-UTR wasamplified from human adult brain cDNA library (Invitrogen) with primers5′-CTCTAGAGAAATATCTTTGCTCCCAGTT-3′ and5′CTCTAGACATGGTCGAATATTATTTATTGTC-3′, and cloned into pCR2.1-TOPOplasmid (Invitrogen) before subcloning into pGL3 promoter plasmid andα-Syn expressing plasmids. The plasmid α-Syn-mUTR containing mutation ofthe miR-7 target site in the α-Syn 3′-UTR was created using theQuikChange site-directed mutagenesis kit (Stratagene) with primers5′-TCTCGAAGTCAACCATCAGCAG-3′ and 5′CTGCTGATGGTTGACTTCGAGA-3′, and DNAsequences were confirmed. Control plasmids EGFR containing 3′-UTR of EGFreceptor, and pri-miR-7-2 expressing premiR-7-2 with 600 bp flankingsequences, were gifts from Dr. Benjamin Purow (University of Virginia).

Western Blot Analysis.

Cell lysates were analyzed by Western blotting as described previouslyusing mouse monoclonal anti-α-Syn antibodies SYN-1, (BD TransductionLab) and LB509, (Zymed)), mouse monoclonal β-actin antibody (Sigma) andrabbit polyclonal anti-GFP antibody (Santa Cruz Biotech.). Banddensities were quantified using NIH Image J.

Quantitative Real-Time RT-PCR (qRT-PCR).

For qRT-PCR of α-Syn, total RNAs were prepared from cells with TRIZOLreagent (GibCo BRL) according to the manufacturer's instructions.Reverse transcription reaction was performed with 1 μg of total RNA per20 μl reaction. Real-time PCR was performed in triplicates with TaqmanPCR Mix (Applied Biosystems Inc., Foster City, Calif.) in the ABI's7900HT Fast Real-Time PCR System. All primers were purchased fromApplied Biosystems Inc. The level of α-Syn mRNA expression wasnormalized to GAPDH mRNA. For qRT-PCR of miR-7, brains from 12-week oldC57/B6 mice were used to prepare total RNA from various regions withmiRCURY™ RNA isolation kit (Exiqon) according to the manufacturer'sprotocol. Reverse transcription was done with miRCURY LNA™ first-strandcDNA kit (Exiqon) and qRT-PCR was performed with miRCURY LNA™ miR-7primer set (Exiqon) using miRCURY LNA™ SYBR Green master mix (Exiqon)according to manufacturer's instruction.

Proteasome Activity Assay.

Cells were lysed in a buffer containing 50 mM Tris-HCl (pH 8.0), 1 mMATP, 10% glycerol, 0.1% NP-40, and lysates were centrifuged. Fiftymicrogram of supernatant protein was used in the assay containing 50 mMTris-HCl (pH 8.0), 2 mM MgCl2, 1 mM ATP and 100 μM fluorogenicsubstrates, such as suc-LLVYAMC, z-LLE-AMC and boc-LRR-AMC (BostonBiochem) to measure chymotrypsin-like, trypsin-like and post-acidicactivity of proteasome, respectively. Assays were carried out at 37° C.for 20 min. and activities were measured in a fluorometer (Victor2,Perkin Elmer) with 380 nm excitation and 460 nm emission filters.Background levels of fluorescence were determined using lysatesincubated with proteasome inhibitor MG-132 (10 μM) for 30 min prior toadding the fluorogenic substrate.

Cell Death Assay.

NS20Y cells transfected with α-Syn-expressing constructs in the absenceor presence of miR-7 were exposed to H2O2, and cell death was assessedby lactate dehydrogenase (LDH) Cytotoxicity Detection Kit (RocheMolecular Biochemicals) as described previously.

Statistical Analysis.

Statistical significance between control and experimental values wasdetermined using Student's t test (paired, two-tailed). All data areexpressed as mean±standard deviations (S.D.).

Example 2 In Vivo Validation of the Role of Specific microRNAs inProtecting Neurons

To validate the ability of miR-7 and other microRNAs that have thepotential to down-regulate α-synuclein expression in the brain, highlyefficient lentiviral vectors have been generated that express miR-7 anda scrambled negative control sequence and injected stereotaxically inthe substantia nigra of wild-type mice unilaterally. The amount of miR-7expression as well as the amount of α-synuclein miRNA expression will bemeasured by real time PCR and α-synuclein protein expression will beassessed by Western blotting. It is expected that α-Synuclein expressionwill be decreased in microRNA injected brains but not in scrambledsequence injected samples. This paradigm will also be employed to assessthe ability of this treatment to protect against the dopaminergicneurotoxin MPTP commonly used to model Parkinson's disease in laboratoryanimals. In alternative experiments, we will use adeno-associated virusas an alternative vector to deliver microRNAs.

Infection into Mouse Brain.

Lentiviral particle mixture was injected into right lateral substantianigra of 8 week old C57/BL mice. After anesthesia, the mice were placedin a stereotaxic frame. After placing mice in the stereotaxic frame, 2μl of highly concentrated viral particles were injected into the nigra(coordinates: AP −3.3 mm, ML −1.2 mm, DV −4.6 mm from bregma) over 5min. After injection, the needle was left in place for 10 min.

Animals will be sacrificed at 3 different time points, 3 weeks, 8 monthsand 20 weeks to assess α-Syn mRNA expression by real time-PCR andprotein expression by Western blot analysis.

Effect of miRNA on MPTP-Intoxicated Model.

MPTP impairs mitochondrial complex I activity, depletes ATP and leads tooxidative stress. It has been used extensively to produce a toxic modelof Parkinson's disease. Since the miRNA species identified by ourstudies are expected to be protective, we hypothesize that miRNAover-expression also protects against MPTP-induced toxicity in mice. Todo this, eight-week old mice will be infected with lenti-LemiR (control)or lenti-miRNA. After two weeks, MPTP (30 mg/kg) will be administeredintraperitoneally to animals, once daily for five consecutive days, andwill be sacrificed 14 days after the final injection. Control mice willreceive saline only. Six to eight mice will comprise each group.Substantia nigra will be dissected quickly and α-synuclein expressionwill be compared by Western blot analysis. We will check thedopaminergic neuron degeneration in substantia nigra. We expect thatmiRNA expression spares dopaminergic neurons from MPTP-induced toxicityin mice. Outcome measures will include immunohistochemistry and cellcounting as well as striatal dopamine and tyrosine hydroxylase content.

Alternative strategies may also be employed including using AAV vectorand evaluate animals at different time points.

Generation of rAAV-miR-7.

Viral vectors harboring pri-miR-7 cDNA sequence (using Sanger miRbasedatabase) will be constructed with AAV vector. Plasmids will beconstructed with a cassette containing chickenβ-actin-promoter/cytomegalovirus enhancer (CAG promoter) that gives highexpression in neuronal cells. As a negative control, we will clonescrambled sequence that does not inhibit any gene expression into thisviral vector. To monitor miR-7 expression easily in the mouse brain, wewill insert Internal Ribosome Entry Sequence (IRES)-GFP expression unitdownstream of miR-7 cDNA, thereby miR-7 and GFP will be expressedbicistronically from a single mRNA. Subsequently, the plasmid DNA,pAAV-miR-7, or pAAV-scramble will be co-transfected with plasmidspHelper and Pack2/1 into HEK293T cells using a standard calciumphosphate method, and 48 hours post-transfection the virus will beharvested. Briefly, crude rAAV supernatants obtained by repeatedfreeze/thaw cycles will be processed for gradient ultracentrifugation.The fractions containing high titer rAAV will be collected and used forinjecting animals. The number of rAAV genome copies will besemi-quantified by PCR within the CMV promoter region using primers5′-GACGTCAATAATGACGTATG-3′ and 5′-GGTAATAGCGATGACTAATACG-3′. Finaltiters will be set to 6-10×10¹¹ genome copies/ml.

In Vitro Infection of rAAV-miR-7.

After generating rAAV-miR-7, we will first test its effectiveness byinfecting HEK293T cells, which we have used successfully to study theeffect of miR-7 on α-Syn expression. We anticipate to detect increasedmiR-7 and decreased α-Synuclein expression in GFP-positiverAAV-miR-7-infected cells but not in negative controlrAAV-scramble-infected cells. For this experiment, in situ hybridizationwill be employed to detect miR-7, and immunocytochemical staining willbe performed to detect α-Syn, as we reported previously. If infectionefficiency approaches nearly 100%, we will check the level of miR-7 byqRT-PCR and α-Syn by Western blot. Subsequently, rAAV-miR-7 withverified effectiveness in vitro will be used for the mouse experiments.

rAAV-miR-7 Gene Transfer into Mouse Brain.

We will inject rAAV-miR-7 or rAAV-scramble into the right lateralsubstantia nigra. For these experiments, we will use 8 week-old C57/BLmice. All stereotaxic surgical procedures are performed asepticallyunder anesthesia with ketamine and xylazine. After placing mice in thestereotaxic frame, 2 μl of highly concentrated viral particles will beinjected into the nigra (coordinates: AP −3.3 mm, ML −1.2 mm, DV −4.6 mmfrom bregma) over 5 min. After injection, the needle will be left inplace for 10 min.

Although a number of factors including capsid serotype and promoterinfluence transduction efficiency, most data indicate that transductionmay increase during the first two months. Another consideration is theduration of miR-7 expression after a single infection. Therefore, wewill sacrifice the animals at 3 different time points, 3 weeks, 8 weeksand 20 weeks to assess the following outcome measures: We will firstcheck the transduction efficiency by examining GFP-positive cells innigral dopaminergic neurons. Staining of 30 μm thick-coronal sectionswith an antibody against tyrosine hydroxylase (TH; Sigma) will beperformed to visualize nigral dopaminergic neurons as red fluorescence.We will determine if the transduced GFP-positive dopaminergic neuronsexpress high-level of miR-7 by in situ hybridization. Because GFP andmiR-7 are produced from a single transcript bicistronically, there willbe high level of miR-7 expression in GFP-positive cells. We will assessthe level of α-Syn expression in GFP-positive nigral dopaminergicneuronal cells. We expect that there will be decreased α-Syn expressionin GFP-positive dopaminergic neurons due to the effect of over-expressedmiR-7. Immunohistochemistry with an antibody to α-Syn (SYN-1, BDtransduction) will be performed to visualize α-Syn expressing cells asred fluorescence. It will be of interest to learn whether injection ofrAAV-miR-7 into the nigra results in reduced α-Syn expression in thestriatum, a process that would require anterograde transport of maturemiR-7 from cell bodies in the nigra to synaptic terminals in thestriatum. Expression levels will be compared between injected andcontralateral non-injected sides, as well as between rAAV-miR-7 andrAAV-scramble injected animals at 3 different time points mentionedabove. We will check the integrity of dopaminergic neurons in substantianigra and terminals in striatum by immunohistochemistry, in order todetermine if rAAV-miR-7 infection per se produces any toxicity todopaminergic neurons. For this, TUNEL (Terminal transferase dUTP nickend labeling) staining, which is positive in apoptotic cells, will beperformed.

Effect of miR-7 in the MPTP-Lesioned Model.

According to our preliminary studies, miR-7 expression is down-regulatedin the midbrain of MPTP-lesioned mice. This finding prompts us to testthe effect of miR-7 over-expression in this model. Since our dataindicate that miR-7 protects cells against α-Syn-mediated toxicity, wehypothesize that over-expressing miR-7 also protects againstMPTP-induced toxicity in mice. The mechanism of such protection willeither be through down-regulating α-Syn, since α-Syn null mice arereportedly relatively resistant to MPTP, or regulation of other genes.For this experiment, eight-week old mice will be infected withrAAV-miR-7 or rAAV-scramble (control) into the nigra as described above.After 1 week, 6 weeks and 18 weeks, MPTP (30 mg/kg) or saline will beadministered intraperitoneally once daily for five consecutive days, andanimals will be sacrificed 14 days after the final injection. We willassess the degeneration of nigral dopaminergic neurons and striatalnerve terminals. We expect that the degree of nigral TH positive neuronloss and striatal dopamine depletion following MPTP administration willbe moderated in rAAV-miR-7-infected mice compared torAAV-scramble-infected animals. Nigral dopaminergic neuron degenerationwill be assessed by cell counting using unbiased stereology. Density ofdopaminergic neuron terminals in the striatum will be assessed by THstaining and ELISA. In addition, we will measure dopamine content instriatal tissues by HPLC with an electrochemical detector.

These outcome measures will be compared with the contralateraluninjected side as well. We expect that over-expressing miR-7 protectsdopaminergic neurons from MPTP-induced toxicity in mice. Throughout theproposed studies, statistical significance between control andexperimental groups will be determined by Analysis of Variance for eachtime point and a significance level of p<0.05.

1-18. (canceled)
 19. A method for decreasing the expression of α-synuclein in a patient in need thereof comprising administering to said patient an effective amount of a composition comprising miRNA-153 (SEQ ID NOs. 3-4).
 20. The method of claim 19, wherein the composition comprising miRNA-153 is administered through a delivery system, and wherein the delivery system comprises at least one of a viral vector, a liposome, a microparticle, capsules, and combinations thereof.
 21. The method of claim 20, wherein the delivery system comprises a viral vector.
 22. The method of claim 19, wherein the patient suffers from Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy.
 23. The method of claim 22, wherein the composition comprising miRNA-153 is administered through a delivery system, and wherein the delivery system comprises at least one of a viral vector, a liposome, a microparticle, capsules, and combinations thereof.
 24. The method of claim 23, wherein the delivery system comprises a viral vector.
 25. A method for treating Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy, in a patient in need thereof comprising administering to said patient an effective amount of a composition comprising miRNA-153 (SEQ ID NOs. 3-4),
 26. The method of claim 25, wherein the composition comprising miRNA-153 is administered through a delivery system, and wherein the delivery system comprises at least one of a viral vector, a liposome, a microparticle, capsules, and combinations thereof
 27. The method of claim 26, wherein the delivery system comprises a viral vector. 